PMID- 30813533
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201001
IS  - 2072-6694 (Print)
IS  - 2072-6694 (Electronic)
IS  - 2072-6694 (Linking)
VI  - 11
IP  - 3
DP  - 2019 Feb 26
TI  - Targeting the Post-Irradiation Tumor Microenvironment in Glioblastoma via 
      Inhibition of CXCL12.
LID - 10.3390/cancers11030272 [doi]
LID - 272
AB  - Radiotherapy is a mainstay in glioblastoma therapy as it not only directly 
      targets tumor cells but also depletes the tumor microvasculature. The resulting 
      intra-tumoral hypoxia initiates a chain of events that ultimately leads to 
      re-vascularization, immunosuppression and, ultimately, tumor-regrowth. The key 
      component of this cascade is overexpression of the CXC-motive chemokine ligand 12 
      (CXCL12), formerly known as stromal-cell derived factor 1 (SDF-1). We here review 
      the role of CXCL12 in recruitment of pro-vasculogenic and immunosuppressive cells 
      and give an overview on future and current drugs that target this axis.
FAU - Giordano, Frank A
AU  - Giordano FA
AUID- ORCID: 0000-0001-5243-4781
AD  - Department of Radiation Oncology, Universitatsmedizin Mannheim, Medical Faculty 
      Mannheim, Heidelberg University, 68167 Mannheim, Germany. Frank.Giordano@umm.de.
FAU - Link, Barbara
AU  - Link B
AD  - Department of Radiation Oncology, Universitatsmedizin Mannheim, Medical Faculty 
      Mannheim, Heidelberg University, 68167 Mannheim, Germany. 
      barbara.link@medma.uni-heidelberg.de.
FAU - Glas, Martin
AU  - Glas M
AD  - Division of Clinical Neurooncology, Department of Neurology and West German 
      Cancer Center (WTZ), University Hospital Essen and German Cancer Consortium, 
      Partner Site University Hospital Essen, University Duisburg-Essen, 45147 Essen, 
      Germany. Martin.Glas@UK-Essen.de.
FAU - Herrlinger, Ulrich
AU  - Herrlinger U
AD  - Division of Clinical Neurooncology, Department of Neurology, University of Bonn 
      Medical Center, 53105 Bonn, Germany. Ulrich.Herrlinger@ukbonn.de.
FAU - Wenz, Frederik
AU  - Wenz F
AD  - CEO, University Medical Center Freiburg, 79110 Freiburg, Germany. 
      frederik.wenz@uniklinik-freiburg.de.
FAU - Umansky, Viktor
AU  - Umansky V
AD  - Skin Cancer Unit, German Cancer Research Center (DKFZ), 69120 Heidelberg, 
      Germany. v.umansky@dkfz.de.
AD  - Department of Dermatology, Venereology and Allergology, University Medical Center 
      Mannheim, Ruprecht-Karl University of Heidelberg, 68167 Mannheim, Germany. 
      v.umansky@dkfz.de.
FAU - Brown, J Martin
AU  - Brown JM
AD  - Department of Neurology, Stanford University School of Medicine, Stanford, CA 
      94305, USA. mbrown@stanford.edu.
FAU - Herskind, Carsten
AU  - Herskind C
AUID- ORCID: 0000-0001-6554-5907
AD  - Department of Radiation Oncology, Universitatsmedizin Mannheim, Medical Faculty 
      Mannheim, Heidelberg University, 68167 Mannheim, Germany. 
      carsten.herskind@medma.uni-heidelberg.de.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20190226
PL  - Switzerland
TA  - Cancers (Basel)
JT  - Cancers
JID - 101526829
PMC - PMC6468743
OTO - NOTNLM
OT  - CXCL12
OT  - glioblastoma
OT  - radiotherapy
COIS- F.A.G.: consultant and speaker for Carl Zeiss Meditec AG, NOXXON Pharma, MSD 
      Sharp and Dohme, Roche Pharma AG, AstraZeneca, Bristol-Myers Squibb and Oncare, 
      holds patents related with Carl Zeiss Meditec AG, co-founder and stakeholder of 
      Implacit. Research grants from Guerbet SA, Carl Zeiss Medotec, Elekta AB and 
      NOXXON Pharma. B.L.: none. M.G.: consulting and advisory role to Roche, Novartis, 
      Daiichi Sankyo, Novocure. Travel support received from Medac, Novocure. Honoraria 
      received from Novartis, Merck, Novocure, Medac, Kyowa Kirin, Bayer. U.H.: 
      Consultant and/or speaker for Roche, Medac, Bristol-Myers Squibb, Novocure, 
      Novartis, Daichii-Sankyo, Riemser, Noxxon. F.W.: advisor, consultant and/or 
      speaker for Celgene GmbH, Roche Pharma AG, Eli Lilly and Company, Ipsen Pharma 
      GmbH, receives travel and research grants from Carl Zeiss Meditec AG and Elekta 
      AB, is on the Carl Zeiss Meditec AG speaker's bureau, holds patents related with 
      Carl Zeiss Meditec AG. V.U.: consultant for NOXXON Pharma. Research grants from 
      NOXXON Pharma and Apogenix. J.M.B.: None. C.H.: teaching the radiobiology of 
      low-energy X-rays for Carl Zeiss Meditec AG; co-inventor of patent held by Carl 
      Zeiss Meditec AG.
EDAT- 2019/03/01 06:00
MHDA- 2019/03/01 06:01
PMCR- 2019/02/26
CRDT- 2019/03/01 06:00
PHST- 2019/01/07 00:00 [received]
PHST- 2019/02/14 00:00 [revised]
PHST- 2019/02/20 00:00 [accepted]
PHST- 2019/03/01 06:00 [entrez]
PHST- 2019/03/01 06:00 [pubmed]
PHST- 2019/03/01 06:01 [medline]
PHST- 2019/02/26 00:00 [pmc-release]
AID - cancers11030272 [pii]
AID - cancers-11-00272 [pii]
AID - 10.3390/cancers11030272 [doi]
PST - epublish
SO  - Cancers (Basel). 2019 Feb 26;11(3):272. doi: 10.3390/cancers11030272.